Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical research of Yang Yin Fu Zheng therapy in HBV associated hepatocellular carcinoma basing on immune microenviroment.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng therapy for patients belong to HBV-HCC.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Ditan Hospital

Criteria

Inclusion Criteria:

1. Confirmed of stage HBV-HCCⅡb、Ⅲa、Ⅲb;

2. Ages Eligible for Study: ≤75 years old;

3. TCM syndrome is deficiency of both Qi and Yin;

4. Confirmed of CHB;

5. Surgery cannot be allowed;

6. Informed consent from the patient.

Exclusion Criteria:

1. Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD;

2. Serious problem of heart, lung, or kidney with severe dysfunction;

3. Pregnant or child breast feeding women;

4. Mental or cognitive disorders;

5. Participating in other drug trials;

6. Who are allergic to the study drug.